ACOG

Alpha Cognition Inc

Healthcare
Biotechnology
$138M market cap

Forecast run · Sep 14, 2026Upside rank 575 of 3,136

Model Signal

ForecastQ Daily Probabilities

53.8%

36.3%

32.4%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$8.90

Price target$17.25

Implied move+93.8%

Analysts1

ForecastQ Portfolios

ACOG is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.